{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hosseini TM"],"funding":["University of California San Diego Altman Clinical and Translational Research Institute","NCI NIH HHS"],"pagination":["1072"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11987906"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(7)"],"pubmed_abstract":["<b>Background/Objectives</b>: HPV+ head and neck squamous cell carcinoma has been shown to have a unique genomic background, requiring researchers to study it as its own distinct type of cancer. HPV+ tumors have been shown to exhibit fewer genetic mutations in cancer drivers as opposed to their HPV- counterparts. In this paper, we explored how targeting post-transcriptional changes, specifically alternative splicing events, could serve as a potential mechanism to treat HPV+ cancer. <b>Methods</b>: Using indisulam, a drug that targets alternative splicing through the degradation of RBM39, we treated various HPV+ and HPV- cell lines and assessed tumor cell viability. We also tested indisulam in vivo to evaluate its effect on tumor volume. Additionally, we analyzed gene expression differences"],"journal":["Cancers"],"pubmed_title":["Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV- Head and Neck Cancer."],"pmcid":["PMC11987906"],"funding_grant_id":["1KL2TR001444","1K08CA276999-01A1"],"pubmed_authors":["Jang SS","Guo T","Hosseini TM","Bendik J"],"additional_accession":[]},"is_claimable":false,"name":"Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV- Head and Neck Cancer.","description":"<b>Background/Objectives</b>: HPV+ head and neck squamous cell carcinoma has been shown to have a unique genomic background, requiring researchers to study it as its own distinct type of cancer. HPV+ tumors have been shown to exhibit fewer genetic mutations in cancer drivers as opposed to their HPV- counterparts. In this paper, we explored how targeting post-transcriptional changes, specifically alternative splicing events, could serve as a potential mechanism to treat HPV+ cancer. <b>Methods</b>: Using indisulam, a drug that targets alternative splicing through the degradation of RBM39, we treated various HPV+ and HPV- cell lines and assessed tumor cell viability. We also tested indisulam in vivo to evaluate its effect on tumor volume. Additionally, we analyzed gene expression differences","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2025-07-03T03:06:05.869Z","creation":"2025-07-03T03:06:05.869Z"},"accession":"S-EPMC11987906","cross_references":{"pubmed":["40227602"],"doi":["10.3390/cancers17071072"]}}